UBT Srl
UBT Srl is an Italian medical device company that develops CE-marked microwave imaging devices—MammoWave (breast lesion detection), BrainWave (stroke classification), and LungWave (lung lesion monitoring)—using low-power radiofrequency signals instead of ionizing radiation, serving hospitals, clinics, and European health systems.
- Company typePrivate
- Founded2015
- HeadquartersPerugia, Italy
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What UBT Srl does
UBT Srl is an Italian medical device company that develops and commercializes microwave imaging devices for diagnostic applications. Founded in 2015 as an academic spin-off of the University of Perugia and headquartered in Rivotorto di Assisi (Perugia), the company operates a wholly-owned UK subsidiary (UBT UK Division, registered 2020) in London. Its core technology exploits low-power radiofrequency signals (1-9 GHz, 1mW) and a proprietary Huygens Principle-based imaging algorithm to detect tissue dielectric inhomogeneities, producing diagnostic images without ionizing radiation. The company is structured as a Benefit Company.
The product portfolio comprises three devices: MammoWave (TRL 9, Class IIa CE-marked under MDR 2017/745 since 2024) for breast lesion detection; BrainWave (TRL 6) for brain stroke detection and classification, designed for ambulance deployment; and LungWave (TRL 4), an early-stage lung lesion detection device. MammoWave has been clinically validated in multicenter trials across Italy, Spain, Portugal, Switzerland, and Poland with 5,000+ women enrolled. Two foundational patents have been granted in Italy, EU, China, and the USA. The company holds ISO 13485 certification and has published 35+ peer-reviewed papers in journals including PLoS ONE, Scientific Reports, IEEE, and BMJ Open.
UBT generates revenue primarily through direct enterprise sales of medical imaging hardware to hospitals, clinics, and national/regional health systems. The company has no publicly disclosed revenue and no institutional venture capital or private equity investment; it has been substantially funded through European Commission grants totaling over €11 million across H2020 SME Instrument Phase 1 (2017), Phase 2 (2018, €1.4M), FETPROACT RadioSpin (2021, €3.8M), and HORIZON-MISS-2021-CANCER MammoScreen (2022, €6M+). The go-to-market relies on direct sales led by a Director of Commercial Operations Italy, supplemented by international medical conference and trade fair participation (ECR, SIRM, BIO, Arab Health, FIME, CIIE) under the EIC Overseas Trade Fairs Programme. Pricing is not publicly disclosed and follows a contact-based enterprise sales model.
UBT Srl firmographics
Firmographics- Name
- UBT Srl
- Legal name
- UBT Srl
- Website
- https://ubt-tech.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- UBT Srl is an Italian medical device company that develops CE-marked microwave imaging devices—MammoWave (breast lesion detection), BrainWave (stroke classification), and LungWave (lung lesion monitoring)—using low-power radiofrequency signals instead of ionizing radiation, serving hospitals, clinics, and European health systems.
- Ownership category
- akta.pro rank
UBT Srl industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mammography & Breast Imaging Systems (HLAHABAF)
Keywords
Where UBT Srl is headquartered
LocationHeadquarters
- HQ city
- Perugia
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
UBT Srl business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: UBT develops and commercializes medical imaging devices (MammoWave, BrainWave, LungWave) based on proprietary microwave imaging technology. Revenue generated from sales of these medical devices to hospitals and clinics.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
UBT Srl product offering
Product offeringCore offering
UBT Srl designs, develops, manufactures and commercializes patented medical imaging devices based on proprietary low-power microwave imaging technology. Its commercial products are MammoWave (breast lesion detection, TRL 9, CE-marked Class IIa under MDR 2017/745), BrainWave (stroke detection/classification, TRL 6), and LungWave (lung lesion detection, TRL 4, in development). Devices use safe radiofrequency signals (1-9 GHz, 1 mW) instead of X-rays and apply a Huygens Principle-based imaging algorithm for diagnostic image reconstruction.
Product overview
UBT Srl develops and commercializes a portfolio of innovative medical imaging devices based on cutting-edge microwave technology. The company offers three patented products: MammoWave (TRL 9) for breast lesion detection, BrainWave (TRL 6) for stroke detection and classification, and LungWave (TRL 4) for lung lesion monitoring. All devices use safe microwave radiofrequency signals instead of ionizing radiation, exploiting dielectric property contrast for diagnostic imaging.
Differentiator
Problem solved
Functional benefit
Products and services
- MammoWave Microwave imaging device for breast lesion detection that uses safe low-power (1 mW) radiofrequency signals in the 1-9 GHz band instead of X-rays. Employs a Huygens Principle-based imaging algorithm to generate breast images highlighting tissue dielectric inhomogeneities with high sensitivity and specificity, including in dense breasts. Examination is performed in a comfortable prone position without breast compression and has no age or frequency restrictions. CE-marked Class IIa medical device under MDR 2017/745; targets hospitals, clinics, and breast screening programs.
- BrainWave Microwave imaging device for brain stroke detection and classification using a wave-guided configuration with two antennas operating at 1-5 GHz and 1 mW power. Differentiates hemorrhagic from ischemic stroke through dielectric property contrast analysis, enabling fast and accurate brain imaging in pre-hospital and emergency settings, including ambulance deployment. Targets emergency medical services, neurology departments, and stroke units.
- LungWave Microwave imaging device for lung lesion detection and monitoring, currently in development at TRL 4. Uses UBT's low-power microwave imaging platform to detect and monitor lung lesions without ionizing radiation.
Quantifiable outcome
- Can potentially expand EU breast cancer screening to additional 98 million women in 20-49 and over 70 age groups
- +2 more outcomes
Companies that use UBT Srl
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
UBT Srl technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
UBT Srl partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- London South Bank University (LSBU)coreSince 2017, UBT collaborates with LSBU's Centre for Bioengineering (BiMEC) for microwave imaging R&D and AI development. UBT sponsors Industrial PhD and Matched Funded Post-PhD positions. LSBU is a key partner in MammoScreen, RadioSpin, and ROVER EU projects.
- MammoScreen ConsortiumcoreHORIZON-MISS-2021-CANCER-02-01 funded consortium: UBT, Toscana Life Sciences Foundation (Italy), LSBU (UK), ELAROS 24/7 Limited (UK), Servicio De Salud De Castilla La Mancha (Spain), Scuola IMT Alti Studi Lucca (Italy), EVITA (Portugal). 48-month project for MammoWave clinical validation on thousands of women.
- RadioSpin ConsortiumcoreH2020-FETPROACT funded consortium: Université de Bordeaux (coordinator), CNRS (France), INL (Portugal), Thales (France), Eurida research (Austria), UBT. 50-month project building hardware neural networks for AI integration into MammoWave.
- ROVER ConsortiumminorH2020 Marie Skłodowska-Curie RISE project: UBT with University of Oulu, University of Florence, LSBU, Oslo University Hospital, Elaros, Yokohama National University, University of Technology Sydney, Asian Institute of Technology, Worcester Polytechnic Institute, University of Nebraska-Lincoln for wireless body-centric systems research.
- DIGITEC SrlcoreLeader in medical imaging software for acquiring, processing and transferring medical images. Partner since 2017. Manages DICOM hospital network distribution and provides risk assessment for electromagnetic fields from medical devices.
- MTIC InterCert SrlcoreItalian certification body that awarded MammoWave CE marking and ISO 13485 certification for UBT.
- Bureau Veritas ItaliacoreCertification body that awarded MammoWave CE marking under MDR 2017/745 regulation.
- Imago7 FoundationminorConsortium for scientific research in magnetic resonance (MR); houses the first and only 7.0 Tesla MR system in Italy. Gianluigi Tiberi coordinates the Radio Frequency laboratory at Imago7 Foundation.
- Hospital Virgen de la Salud Toledo / Hospital Universitario de ToledocoreMammoWave installed November 2019. Three clinical studies (including ongoing MammoScreen) activated at this hospital. Partner in MammoScreen project. Official start of clinical trials from November 2020.
- Ospedale Policlinico San Martino GenovacoreThree clinical studies related to MammoWave clinical validation activated at this hospital. Acting as Italian coordinator center for MammoScreen project clinical trial.
- Azienda Ospedaliera di Perugia / Azienda Ospedaliera S. Maria della MisericordiacoreFirst MammoWave feasibility clinical trial conducted here, successfully completed 2020. Dr. Michele Duranti serves as Principal Investigator.
- Azienda Ospedaliero Universitaria di PisacoreBrainWave feasibility clinical trial activated in 2021 under Prof. Mirco Cosottini (Director, Neurology Department).
- Humanitas Research Hospital MilanocoreClinical trial site for MammoWave breast imaging device as part of H2020-SME-Instrument-Phase2 international study.
- MTA - Medical Trials AnalysisminorCRO that collaborated on clinical trial protocol for MammoWave international clinical investigation (ClinicalTrials.gov NCT04253366).
- ARPA UmbriaminorPartnership for defining dedicated protocols for electromagnetic field measurements in working and hospital environments.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
UBT Srl competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Major mammography equipment vendor (MAMMOMAT systems) with global commercial reach and deep hospital integration. Targets the same breast imaging procurement budgets as MammoWave.
- Hologic: Leading global mammography and breast imaging incumbent (Selenia Dimensions 3D mammography). Operates at much larger scale with established hospital relationships across the same breast screening category UBT targets.
- Philips Healthcare: Global medical imaging incumbent (MicroDose mammography). Stefano Orselli at UBT previously led Philips Healthcare Italy, illustrating the competitive overlap in breast imaging enterprise sales.
- GE Healthcare: Sells Senographe mammography systems and broader radiology portfolio. Comparable in providing imaging hardware to hospitals and competes for the same screening capital equipment budgets.
Emerging players
- Delphinus Medical Technologies: Developed SoftVue, a non-ionizing breast imaging system using ultrasound tomography. Competes in the same 'radiation-free breast imaging' category as MammoWave from a different physical modality.
- iCAD: Provides AI-powered breast imaging solutions (ProFound AI for DBT, mammography CAD). Relevant peer because UBT also incorporates AI classification algorithms into MammoWave for lesion detection.
- QT Ultrasound: Commercializes QTscan, a non-ionizing ultrasound-based breast imaging system positioned as a radiation-free alternative to mammography — directly comparable use case to MammoWave.
- Volpara Health: Software platform for breast screening workflow, image quality, and risk assessment. Comparable in supporting population-based breast cancer screening programs — the same segment UBT targets via MammoScreen.
- Seno Medical Instruments: Developed Imagio optoacoustic breast imaging system, another non-ionizing modality pursuing the same 'no radiation, dense-breast friendly' positioning in breast lesion diagnosis.
Direct peers
- Micrima: UK-based company developing MARIA microwave breast imaging system — the closest direct competitor to MammoWave using the same dielectric imaging approach for radiation-free breast examination.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
UBT Srl social profiles
Digital presenceUBT Srl compliance and trust
Trust signalCompliance2 records
UBT Srl financial estimates
Financial estimateRevenue estimate
Valuation estimate
UBT Srl leadership team
Management profileNumber of profiles
Profiles17 records
UBT Srl subsidiaries and ownership
Company hierarchySubsidiaries1 record
UBT Srl funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UBT Srl M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UBT Srl
What does UBT Srl do?
UBT Srl designs, develops, manufactures and commercializes patented medical imaging devices based on proprietary low-power microwave imaging technology. Its commercial products are MammoWave (breast lesion detection, TRL 9, CE-marked Class IIa under MDR 2017/745), BrainWave (stroke detection/classification, TRL 6), and LungWave (lung lesion detection, TRL 4, in development). Devices use safe radiofrequency signals (1-9 GHz, 1 mW) instead of X-rays and apply a Huygens Principle-based imaging algorithm for diagnostic image reconstruction.
Is UBT Srl a public or private company?
UBT Srl is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was UBT Srl founded?
UBT Srl was founded in 2015. It employs 1 to 10 people.
Where is UBT Srl based?
UBT Srl is headquartered in Perugia, Italy, in the Europe region.
How does UBT Srl make money?
One revenue line is on record: medical Device Sales.
Who are UBT Srl's main competitors?
Broad incumbents on record are Siemens Healthineers, Hologic, Philips Healthcare and GE Healthcare. Emerging players are Delphinus Medical Technologies, iCAD, QT Ultrasound, Volpara Health and Seno Medical Instruments. Micrima is listed as a direct peer.
Does UBT Srl have an API?
No public API is recorded for UBT Srl.
What industry is UBT Srl in?
UBT Srl's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 3391 and its SIC code is 3841.